SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-K’ for 12/31/14 – ‘R7’

On:  Wednesday, 3/4/15, at 5:08pm ET   ·   For:  12/31/14   ·   Accession #:  1628280-15-1461   ·   File #:  1-36297

Previous ‘10-K’:  ‘10-K’ on 3/28/14 for 12/31/13   ·   Next:  ‘10-K’ on 3/4/16 for 12/31/15   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/15  Revance Therapeutics, Inc.        10-K       12/31/14  101:15M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.45M 
 2: EX-10.25    Material Contract                                   HTML     35K 
 3: EX-10.40    Material Contract                                   HTML     63K 
 4: EX-10.42    Material Contract                                   HTML    206K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     29K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     32K 
70: R1          Document and Entity Information                     HTML     59K 
56: R2          Consolidated Balance Sheets                         HTML    140K 
68: R3          Consolidated Balance Sheets (Parenthetical)         HTML     63K 
73: R4          Consolidated Statement of Operations and            HTML    109K 
                Comprehensive Loss                                               
92: R5          Consolidated Statements of Changes in Convertible   HTML    256K 
                Preferred Stock and of Stockholders’ Equity                      
                (Deficit)                                                        
59: R6          Consolidated Statements of Changes in Convertible   HTML     41K 
                Preferred Stock and of Stockholders’ Equity                      
                (Deficit) (Parenthetical)                                        
67: R7          Consolidated Statements of Cash Flows               HTML    234K 
51: R8          The Company and Basis of Presentation               HTML     44K 
41: R9          Summary of Significant Accounting Policies          HTML     83K 
93: R10         License Agreements                                  HTML     37K 
75: R11         Medicis Settlement                                  HTML     43K 
74: R12         Fair Value Measurements                             HTML    123K 
80: R13         Balance Sheet Components                            HTML     82K 
81: R14         Notes Payable                                       HTML     60K 
78: R15         Convertible Notes, Warrants, and Related            HTML     61K 
                Derivatives                                                      
82: R16         Interest Expense                                    HTML     62K 
69: R17         Commitments and Contingencies                       HTML     47K 
71: R18         Common Stock                                        HTML     51K 
77: R19         Convertible Preferred Stock                         HTML     62K 
101: R20         Warrants                                            HTML     64K  
88: R21         Stock Option Plan                                   HTML    232K 
63: R22         Net Income (Loss) per Share Attributable to Common  HTML     80K 
                Stockholders                                                     
76: R23         Income Taxes                                        HTML     93K 
65: R24         Defined Contribution Plan                           HTML     34K 
32: R25         Subsequent Events                                   HTML     37K 
89: R26         Quarterly Results of Operations (Unaudited)         HTML     86K 
97: R27         Summary of Significant Accounting Policies          HTML    147K 
                (Policies)                                                       
46: R28         Fair Value Measurements (Tables)                    HTML    117K 
45: R29         Balance Sheet Components (Tables)                   HTML     85K 
49: R30         Notes Payable (Tables)                              HTML     42K 
50: R31         Convertible Notes, Warrants, and Related            HTML     41K 
                Derivatives (Tables)                                             
52: R32         Interest Expense (Tables)                           HTML     60K 
24: R33         Commitments and Contingencies (Tables)              HTML     37K 
86: R34         Common Stock (Tables)                               HTML     48K 
61: R35         Convertible Preferred Stock (Tables)                HTML     52K 
64: R36         Warrants (Tables)                                   HTML     52K 
36: R37         Stock Option Plan (Tables)                          HTML    210K 
100: R38         Net Income (Loss) per Share Attributable to Common  HTML     81K  
                Stockholders (Tables)                                            
16: R39         Income Taxes (Tables)                               HTML     83K 
53: R40         Quarterly Results of Operations (Unaudited)         HTML     85K 
                (Tables)                                                         
91: R41         The Company and Basis of Presentation - Additional  HTML     90K 
                Information (Detail)                                             
34: R42         Summary of Significant Accounting Policies          HTML     71K 
                (Details)                                                        
44: R43         License Agreements (Details)                        HTML     52K 
48: R44         Medicis Settlement - Additional Information         HTML     79K 
                (Detail)                                                         
57: R45         Fair Value Measurements - Schedule of Fair Value    HTML     89K 
                of Financial Instruments (Detail)                                
23: R46         Fair Value Measurements - Summary of Changes in     HTML     95K 
                Fair Value of Financial Instruments (Detail)                     
40: R47         Fair Value Measurements (Narrative) (Details)       HTML     31K 
18: R48         Balance Sheet Components - Additional Information   HTML     38K 
                (Detail)                                                         
90: R49         Balance Sheet Components - Schedule of Property     HTML     55K 
                and Equipment, Net (Detail)                                      
33: R50         Balance Sheet Components - Schedule of Prepaid      HTML     42K 
                Expenses and Other Current Assets (Detail)                       
87: R51         Balance Sheet Components - Schedule of Accruals     HTML     57K 
                and Other Current Liabilities (Detail)                           
37: R52         Balance Sheet Components - Schedule of Other        HTML     40K 
                Non-Current Assets (Detail)                                      
54: R53         Notes Payable - Hercules Notes Payable (Detail)     HTML     97K 
17: R54         Notes Payable - Essex Capital Notes (Detail)        HTML    111K 
21: R55         Notes Payable - Summary of Aggregate Total Future   HTML     37K 
                Minimum Lease Payments under the Financing                       
                Obligation (Detail)                                              
47: R56         Notes Payable - Summary of Future Principal         HTML     44K 
                Payments under the Notes Payable (Detail)                        
27: R57         Convertible Notes, Warrants, and Related            HTML    154K 
                Derivatives - Additional Information (Detail)                    
94: R58         Convertible Notes, Warrants, and Related            HTML     46K 
                Derivatives - Fair Value Assumptions Using "Monte                
                Carle" Simulation (Details)                                      
60: R59         Interest Expense - Summary of Interest Expense by   HTML     56K 
                Cash and Non-Cash Components (Detail)                            
79: R60         Commitments and Contingencies - Additional          HTML     44K 
                Information (Detail)                                             
39: R61         Commitments and Contingencies - Schedule of Future  HTML     48K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
42: R62         Common Stock - Additional Information (Detail)      HTML     61K 
85: R63         Convertible Preferred Stock - Additional            HTML    137K 
                Information (Detail)                                             
83: R64         Convertible Preferred Stock - Outstanding           HTML     80K 
                (Details)                                                        
62: R65         Warrants - Additional Information (Detail)          HTML    151K 
84: R66         Warrants - Schedule of Warrants (Details)           HTML     55K 
38: R67         Warrants - Assumptions Using Black-Scholes Model    HTML     39K 
                (Details)                                                        
66: R68         Stock Option Plan - Additional Information          HTML    140K 
                (Detail)                                                         
96: R69         Stock Option Plan - Summary of Stock Option and     HTML    175K 
                Restricted Stock Award Activity (Details)                        
20: R70         Stock Option Plan - Stock Options Outstanding and   HTML     89K 
                Exercisable (Details)                                            
31: R71         Stock Option Plan - Summary of Restricted Stock     HTML     64K 
                Award Activity (Details)                                         
55: R72         Stock Option Plan - Fair Value Assumptions          HTML     59K 
                (Details)                                                        
26: R73         Stock Option Plan - Schedule of Stock-based         HTML     41K 
                Compensation Expense (Details)                                   
99: R74         Net Income (Loss) per Share Attributable to Common  HTML    104K 
                Stockholders - Schedule of Computation of Basic                  
                and Diluted Net Income (Loss) Per Share                          
                Attributable to Common Stockholders (Detail)                     
35: R75         Net Income (Loss) per Share Attributable to Common  HTML     50K 
                Stockholders - Summary of Common Stock Equivalents               
                Excluded from Computation of Diluted Net Income                  
                (Loss) Per Share (Detail)                                        
28: R76         Income Taxes - Additional Information (Detail)      HTML     61K 
30: R77         Income Taxes - Deferred Tax Assets and Liabilities  HTML     61K 
                (Details)                                                        
22: R78         Income Taxes - Effective Tax Rate Reconciliation    HTML     58K 
                (Details)                                                        
25: R79         Income Taxes - Unrecognized Tax Benefits (Details)  HTML     40K 
72: R80         Defined Contribution Plan - Additional Information  HTML     31K 
                (Details)                                                        
29: R81         Subsequent Events - Additional Information          HTML     82K 
                (Details)                                                        
95: R82         Quarterly Results of Operations (Unaudited) -       HTML     67K 
                Additional Information (Details)                                 
98: XML         IDEA XML File -- Filing Summary                      XML    166K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX    270K 
43: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.07M 
10: EX-101.INS  XBRL Instance -- rvnc-20141231                       XML   3.11M 
12: EX-101.CAL  XBRL Calculations -- rvnc-20141231_cal               XML    254K 
13: EX-101.DEF  XBRL Definitions -- rvnc-20141231_def                XML    895K 
14: EX-101.LAB  XBRL Labels -- rvnc-20141231_lab                     XML   2.31M 
15: EX-101.PRE  XBRL Presentations -- rvnc-20141231_pre              XML   1.37M 
11: EX-101.SCH  XBRL Schema -- rvnc-20141231                         XSD    250K 
58: ZIP         XBRL Zipped Folder -- 0001628280-15-001461-xbrl      Zip    322K

‘R7’   —   Consolidated Statements of Cash Flows

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (62,917)us-gaap_NetIncomeLoss $ (52,448)us-gaap_NetIncomeLoss $ (58,259)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 2,051us-gaap_Depreciation 1,881us-gaap_Depreciation 1,777us-gaap_Depreciation
Amortization of discount on debt and capital leases 1,250us-gaap_AmortizationOfDebtDiscountPremium 4,128us-gaap_AmortizationOfDebtDiscountPremium 7,427us-gaap_AmortizationOfDebtDiscountPremium
Amortization of debt issuance cost 203us-gaap_AmortizationOfFinancingCosts 217us-gaap_AmortizationOfFinancingCosts 300us-gaap_AmortizationOfFinancingCosts
Revaluation of derivative liabilities associated with convertible notes (4,032)us-gaap_GainLossOnDerivativeInstrumentsNetPretax (2,660)us-gaap_GainLossOnDerivativeInstrumentsNetPretax (13,860)us-gaap_GainLossOnDerivativeInstrumentsNetPretax
Revaluation of derivative liabilities associated with the Medicis settlement 320rvnc_GainLossonDerivativeInstrumentsContractNetPretax (47)rvnc_GainLossonDerivativeInstrumentsContractNetPretax 0rvnc_GainLossonDerivativeInstrumentsContractNetPretax
Revaluation of common stock warrant liability 2,151us-gaap_FairValueAdjustmentOfWarrants 621us-gaap_FairValueAdjustmentOfWarrants 0us-gaap_FairValueAdjustmentOfWarrants
Revaluation of convertible preferred stock warrant liability 210rvnc_RevaluationOfConvertibleRedeemablePreferredStockWarrants (425)rvnc_RevaluationOfConvertibleRedeemablePreferredStockWarrants (125)rvnc_RevaluationOfConvertibleRedeemablePreferredStockWarrants
Extinguishment of warrant liability upon exercise of put option by warrant holder 1,356rvnc_ExtinguishmentofWarrantLiabilityUponExerciseofPutOption 0rvnc_ExtinguishmentofWarrantLiabilityUponExerciseofPutOption 0rvnc_ExtinguishmentofWarrantLiabilityUponExerciseofPutOption
Convertible preferred stock warrant modification remeasurement adjustment 0rvnc_ConversionOfConvertiblePreferredStockWarrant 1,168rvnc_ConversionOfConvertiblePreferredStockWarrant 0rvnc_ConversionOfConvertiblePreferredStockWarrant
Loss on extinguishment of 2013 Notes 8,331us-gaap_GainsLossesOnExtinguishmentOfDebt 0us-gaap_GainsLossesOnExtinguishmentOfDebt 0us-gaap_GainsLossesOnExtinguishmentOfDebt
Stock-based compensation expense 6,530us-gaap_ShareBasedCompensation 548us-gaap_ShareBasedCompensation 79us-gaap_ShareBasedCompensation
Interest on convertible notes converted to convertible preferred stock 0rvnc_InterestExpenseOnNotesPayable 9,220rvnc_InterestExpenseOnNotesPayable 18,830rvnc_InterestExpenseOnNotesPayable
Interest for 2013 Notes and Essex Notes upon issuance, non-cash 271us-gaap_InterestExpenseDebt 273us-gaap_InterestExpenseDebt 0us-gaap_InterestExpenseDebt
Capitalized interest (972)rvnc_InterestExpenseCapitalized (453)rvnc_InterestExpenseCapitalized 0rvnc_InterestExpenseCapitalized
Fair value of common stock warrants issued 379us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 0us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 0us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Effective interest on financing obligation 28us-gaap_FinancingInterestExpense 0us-gaap_FinancingInterestExpense 0us-gaap_FinancingInterestExpense
Modification of Series C-3 convertible preferred stock in accordance with Medicis settlement agreement 0rvnc_ModificationOfPreferredStockInAccordanceWithSettlementAgreement 0rvnc_ModificationOfPreferredStockInAccordanceWithSettlementAgreement (3,225)rvnc_ModificationOfPreferredStockInAccordanceWithSettlementAgreement
Derivative liabilities recognized as result of Medicis settlement agreement 0rvnc_DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement 0rvnc_DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement 15,268rvnc_DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets (999)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 422us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (1,125)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Other non-current assets (1,621)us-gaap_IncreaseDecreaseInOtherNoncurrentAssets (2,770)us-gaap_IncreaseDecreaseInOtherNoncurrentAssets 257us-gaap_IncreaseDecreaseInOtherNoncurrentAssets
Accounts payable (3,399)us-gaap_IncreaseDecreaseInAccountsPayableTrade 3,193us-gaap_IncreaseDecreaseInAccountsPayableTrade 1,028us-gaap_IncreaseDecreaseInAccountsPayableTrade
Accruals and other current liabilities 2,394us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities (3,915)us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities 2,976us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
Payments against Medicis liabilities (7,073)us-gaap_IncreaseDecreaseInDerivativeLiabilities (6,927)us-gaap_IncreaseDecreaseInDerivativeLiabilities 0us-gaap_IncreaseDecreaseInDerivativeLiabilities
Deferred rent 549us-gaap_IncreaseDecreaseInPrepaidRent 133us-gaap_IncreaseDecreaseInPrepaidRent 238us-gaap_IncreaseDecreaseInPrepaidRent
Deferred revenue (83)us-gaap_IncreaseDecreaseInDeferredRevenue 83us-gaap_IncreaseDecreaseInDeferredRevenue (10,500)us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash used in operating activities (55,073)us-gaap_NetCashProvidedByUsedInOperatingActivities (47,758)us-gaap_NetCashProvidedByUsedInOperatingActivities (38,914)us-gaap_NetCashProvidedByUsedInOperatingActivities
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchases of property and equipment (6,975)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (6,477)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (319)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Change in restricted cash 75us-gaap_IncreaseDecreaseInRestrictedCash 75us-gaap_IncreaseDecreaseInRestrictedCash 75us-gaap_IncreaseDecreaseInRestrictedCash
Net cash used in investing activities (6,900)us-gaap_NetCashProvidedByUsedInInvestingActivities (6,402)us-gaap_NetCashProvidedByUsedInInvestingActivities (244)us-gaap_NetCashProvidedByUsedInInvestingActivities
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from issuance of common stock, net of deferred follow-on public offering costs 131,880us-gaap_ProceedsFromIssuanceOfCommonStock 0us-gaap_ProceedsFromIssuanceOfCommonStock 0us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds from issuance of common stock, net of deferred initial public offering costs 102,672us-gaap_ProceedsFromIssuanceInitialPublicOffering 0us-gaap_ProceedsFromIssuanceInitialPublicOffering 0us-gaap_ProceedsFromIssuanceInitialPublicOffering
Proceeds from issuance of convertible notes and notes payable 6,750us-gaap_ProceedsFromNotesPayable 21,903us-gaap_ProceedsFromNotesPayable 18,170us-gaap_ProceedsFromNotesPayable
Principal payments made on capital leases and financing obligation (228)us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities (982)us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities (1,154)us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities
Principal payments made on notes payable (12,316)us-gaap_RepaymentsOfNotesPayable (7,594)us-gaap_RepaymentsOfNotesPayable (3,403)us-gaap_RepaymentsOfNotesPayable
Proceeds from the exercise of stock options and employee stock purchase plan 1,771us-gaap_ProceedsFromStockOptionsExercised 11us-gaap_ProceedsFromStockOptionsExercised 6us-gaap_ProceedsFromStockOptionsExercised
Payments to settle warrants (1,438)us-gaap_PaymentsForRepurchaseOfWarrants 0us-gaap_PaymentsForRepurchaseOfWarrants 0us-gaap_PaymentsForRepurchaseOfWarrants
Proceeds from the exercise of common stock warrants 0us-gaap_ProceedsFromIssuanceOfWarrants 7us-gaap_ProceedsFromIssuanceOfWarrants 1us-gaap_ProceedsFromIssuanceOfWarrants
Proceeds from issuance of convertible preferred stock, net 0us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock 40,646us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock 0us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Net cash provided by financing activities 229,091us-gaap_NetCashProvidedByUsedInFinancingActivities 53,991us-gaap_NetCashProvidedByUsedInFinancingActivities 13,620us-gaap_NetCashProvidedByUsedInFinancingActivities
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 167,118us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (169)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (25,538)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
CASH AND CASH EQUIVALENTS — Beginning of period 3,914us-gaap_CashAndCashEquivalentsAtCarryingValue 4,083us-gaap_CashAndCashEquivalentsAtCarryingValue 29,621us-gaap_CashAndCashEquivalentsAtCarryingValue
CASH AND CASH EQUIVALENTS — End of period 171,032us-gaap_CashAndCashEquivalentsAtCarryingValue 3,914us-gaap_CashAndCashEquivalentsAtCarryingValue 4,083us-gaap_CashAndCashEquivalentsAtCarryingValue
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:      
Cash paid for interest 1,182us-gaap_InterestPaid 1,590us-gaap_InterestPaid 2,302us-gaap_InterestPaid
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:      
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock 123,982us-gaap_ConversionOfStockAmountConverted1 0us-gaap_ConversionOfStockAmountConverted1 0us-gaap_ConversionOfStockAmountConverted1
Conversion of 2013 Notes into common stock 26,206us-gaap_DebtConversionOriginalDebtAmount1 0us-gaap_DebtConversionOriginalDebtAmount1 0us-gaap_DebtConversionOriginalDebtAmount1
Issuance of common stock upon net exercise of common stock warrants in connection with IPO 6,490rvnc_IssuanceOfCommonStockUponNetExerciseOfWarrants 0rvnc_IssuanceOfCommonStockUponNetExerciseOfWarrants 0rvnc_IssuanceOfCommonStockUponNetExerciseOfWarrants
Fair value in excess of debt host for derivative liabilities associated with convertible notes 1,050us-gaap_NotesAssumed1 5,750us-gaap_NotesAssumed1 2,255us-gaap_NotesAssumed1
Deferred initial public offering costs 4,028rvnc_NoncashDeferredInitialPublicOfferingCosts 2,490rvnc_NoncashDeferredInitialPublicOfferingCosts 0rvnc_NoncashDeferredInitialPublicOfferingCosts
Deferred follow-on public offering costs 546rvnc_NonCashDeferredFollowonPublicOfferingCosts 0rvnc_NonCashDeferredFollowonPublicOfferingCosts 0rvnc_NonCashDeferredFollowonPublicOfferingCosts
Conversion of preferred stock warrants to common stock warrants 1,441rvnc_ConversionOfPreferredStockWarrantsToCommonStockWarrants 0rvnc_ConversionOfPreferredStockWarrantsToCommonStockWarrants 0rvnc_ConversionOfPreferredStockWarrantsToCommonStockWarrants
Conversion of Essex Notes into financing obligations 1,095us-gaap_DebtConversionConvertedInstrumentAmount1 0us-gaap_DebtConversionConvertedInstrumentAmount1 0us-gaap_DebtConversionConvertedInstrumentAmount1
Termination of stock option repurchase right 58rvnc_TerminationofStockOptionRepurchaseRightNoncash 0rvnc_TerminationofStockOptionRepurchaseRightNoncash 0rvnc_TerminationofStockOptionRepurchaseRightNoncash
Capital contribution on the extinguishment of the prior convertible preferred stock 0us-gaap_ConversionOfStockAmountIssued1 74,894us-gaap_ConversionOfStockAmountIssued1 0us-gaap_ConversionOfStockAmountIssued1
Capital contribution on the extinguishment of the 2011 Notes 0us-gaap_ExtinguishmentOfDebtAmount 32,008us-gaap_ExtinguishmentOfDebtAmount 0us-gaap_ExtinguishmentOfDebtAmount
Deemed dividend on issuance of Series E-5 convertible preferred stock 0rvnc_DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock 177rvnc_DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock 0rvnc_DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock
Issuance of common stock warrants in connection with Series E-5 convertible preferred stock financing 0rvnc_IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing 4,272rvnc_IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing 153rvnc_IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing
Issuance of common stock warrants in connection with the 2013 Notes 981rvnc_IssuanceOfCommonStockWarrants 2,737rvnc_IssuanceOfCommonStockWarrants 0rvnc_IssuanceOfCommonStockWarrants
Property and equipment purchases included in accounts payable and accruals and other current liabilities 1,348us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 2,285us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 0us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
Issuance of convertible preferred stock warrants 80rvnc_IssuanceOfConvertiblePreferredStockWarrants 139rvnc_IssuanceOfConvertiblePreferredStockWarrants 0rvnc_IssuanceOfConvertiblePreferredStockWarrants
Fair value of common stock warrants issued $ 379rvnc_FairValueofWarrantsIssued $ 0rvnc_FairValueofWarrantsIssued $ 0rvnc_FairValueofWarrantsIssued

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/4/15S-3
For Period end:12/31/14ARS
12/31/1310-K,  DRS,  DRS/A,  S-1
12/31/12
 List all Filings 
↑Top
Filing Submission 0001628280-15-001461   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 4, 4:21:52.1am ET